CRISPR Screening & Functional Genomics Patents

CRISPR screening / functional genomics patents cover pooled-screening innovations; CRISPRi/CRISPRa innovations; single-cell-screen (Perturb-seq) innovations; and sgRNA-library, analysis, and application innovations — with IP held by research institutions, genomics-tools companies, and single-cell firms (in a field systematically perturbing genes with CRISPR to discover their FUNCTION and find drug targets). WHY CRISPR SCREENING: to understand which genes drive a biological process or disease (and find drug targets), researchers PERTURB many genes and observe the effect; CRISPR makes this systematic and genome-wide — knocking out (or inhibiting/activating) thousands of genes in parallel and reading out which perturbations change a PHENOTYPE (e.g., cancer-cell survival, drug resistance); CRISPR screening has transformed functional genomics and target discovery. MAJOR CRISPR-SCREENING PATENT HOLDERS: BROAD INSTITUTE / GENETIC PERTURBATION PLATFORM (GPP) — foundational pooled-screening methods and optimized sgRNA libraries (Doench, Zhang); SYNTHEGO, CELLECTA, HORIZON DISCOVERY/REVVITY (screening reagents/services); TWIST BIOSCIENCE (synthetic sgRNA libraries); 10x GENOMICS (Perturb-seq single-cell screening); and DepMap/Sanger (cancer dependency maps). Critically, the FOUNDATIONAL CRISPR-Cas9 IP (Broad vs UC Berkeley) underlies screening. Pooled screening, CRISPRi/a, single-cell Perturb-seq, and sgRNA libraries/analysis/applications are the core CRISPR-screening patent domains — and optimized libraries, CRISPRi/a, Perturb-seq, in vivo screens, and analysis are the open whitespace.

Pooled-screening innovations; CRISPRi (interference) innovations; CRISPRa (activation) innovations; and sgRNA-library-design innovations represent core CRISPR-screening patent domains — and the screening modality (knockout vs knockdown vs activation) and the quality of the guide-RNA LIBRARY determine what the screen can discover. POOLED-SCREENING PATENTS: introducing a LIBRARY of guide RNAs (each targeting a different gene) into a cell population (usually via lentivirus, one guide per cell), applying a selection/phenotype, and SEQUENCING which guides are ENRICHED or DEPLETED (dropout) to identify genes affecting the phenotype — the pooled-screen workflow, selection schemes, and readout are core method IP. CRISPRi (INTERFERENCE) PATENTS: using catalytically-dead Cas9 (dCas9) fused to a REPRESSOR to KNOCK DOWN (not cut) gene expression — enabling reversible/tunable loss-of-function screens (and avoiding DNA-cut toxicity); CRISPRi systems/screens are high-value. CRISPRa (ACTIVATION) PATENTS: dCas9 fused to an ACTIVATOR to OVEREXPRESS genes — gain-of-function screens (which genes, when turned UP, drive a phenotype); CRISPRa systems are distinct, valuable IP. sgRNA-LIBRARY-DESIGN PATENTS: designing the guide-RNA library — genome-wide coverage, OPTIMIZED guides for high ON-TARGET activity and minimal OFF-TARGET effects (design rules, e.g., Doench/Brunello/GeCKO), multiplexing, and tiling/saturating libraries; library quality is critical to screen success (and many libraries are published/shared — an FTO/whitespace nuance). Pooled-screen methods, CRISPRi/CRISPRa systems, and optimized sgRNA libraries are the highest-value modality IP because the perturbation type and library quality determine the screen's power and the genes it can discover.

Single-cell-screen (Perturb-seq) innovations; in-vivo and complex-readout innovations; base/prime-editing-screen innovations; and analysis and application (dependency/target) innovations represent additional CRISPR-screening patent domains — and richer phenotype readouts (single-cell, in vivo), new editing modalities, and the analysis/applications are where modern value concentrates. SINGLE-CELL-SCREEN (PERTURB-SEQ) PATENTS: combining CRISPR perturbation with SINGLE-CELL RNA-SEQUENCING — each cell's perturbation (guide) AND its transcriptome are read together, giving a rich, high-dimensional phenotype (not just survival) — PERTURB-SEQ / CROP-seq methods, guide-capture, and combined readout (10x Genomics, Broad); single-cell screening is a major, high-value advance (and intersects single-cell-sequencing IP/FTO). IN-VIVO / COMPLEX-READOUT PATENTS: running screens IN VIVO (in animals/tumors) and with complex selectable phenotypes (FACS-based, reporter, spatial); in vivo screening is harder and valuable. BASE/PRIME-EDITING-SCREEN PATENTS: screens using base/prime editors to install specific variants (e.g., saturation mutagenesis of a gene to map functional variants), expanding beyond knockout; variant-effect screening is an emerging frontier. ANALYSIS / APPLICATION PATENTS: computational analysis (e.g., MAGeCK, hit-calling, statistical models), and applications — drug-TARGET discovery, cancer DEPENDENCY mapping (DepMap — which genes cancer cells depend on), synthetic-lethality, drug-resistance mechanisms, and target validation; analysis and target-discovery applications are valuable (often software/data). Perturb-seq single-cell screening, in vivo/complex-readout screens, variant-effect (base/prime-editing) screens, and analysis/target-discovery are the highest-value modern IP because rich phenotypes, physiological context, variant resolution, and actionable target discovery define the field's competitive frontier.

CRISPR screening startup IP strategy must navigate the FOUNDATIONAL CRISPR-Cas9 IP (Broad vs UC Berkeley — a famous dispute, with licensing required to use Cas9 commercially), Broad/GPP pooled-screening and library IP, single-cell (10x) FTO, the published/shared-library nuance, the screening-method and analysis realities, the platform-vs-target-discovery business models, and a landscape where screening methods, CRISPRi/a, Perturb-seq, libraries, and analysis are the durable assets; understand that foundational Cas9 is licensed and many libraries/methods are published, so the durable IP is in novel screening methods, CRISPRi/a systems, Perturb-seq/single-cell, variant-effect screens, and analysis/applications — with Cas9 and single-cell FTO mattering, and that screen power, readout richness, target-discovery value, and FTO matter as much as patents; identify whitespace in Perturb-seq, variant-effect screens, and analysis. CRISPR-SCREENING STARTUP IP STRATEGY: FOUNDATIONAL Cas9 IS LICENSED (BROAD/UC) AND MANY LIBRARIES ARE PUBLISHED — METHODS, CRISPRi/a, PERTURB-SEQ, AND ANALYSIS ARE THE IP: you'll license Cas9 and many sgRNA libraries are public, so patent novel screening methods, CRISPRi/a systems, single-cell/Perturb-seq, variant-effect screens, and analysis — and account for Cas9 + single-cell FTO; PERTURB-SEQ (SINGLE-CELL SCREENING) IS THE HIGH-VALUE FRONTIER: combining perturbation + single-cell readout gives rich phenotypes — high-value methods (but intersects 10x single-cell FTO); CRISPRi/CRISPRa EXPAND BEYOND KNOCKOUT: reversible knockdown (CRISPRi) and gain-of-function (CRISPRa) screens are distinct, valuable modalities; OPTIMIZED LIBRARIES MATTER BUT MANY ARE PUBLIC: guide design (on-target/off-target) is critical, but key libraries are shared — differentiate with novel/specialized libraries (tiling, in vivo, base-editing); VARIANT-EFFECT (BASE/PRIME-EDITING) SCREENS ARE EMERGING WHITESPACE: saturation variant screens map functional variants — a frontier; ANALYSIS/TARGET-DISCOVERY IS WHERE COMMERCIAL VALUE COMPOUNDS: hit-calling, dependency maps, and validated drug targets (often data/software + the targets themselves) are the payoff; PLATFORM VS TARGET-DISCOVERY MODEL SHAPES IP: selling screening tools/services vs discovering own drug targets changes what you protect (and target discoveries are valuable IP); IN VIVO/COMPLEX READOUTS ADD PHYSIOLOGICAL RELEVANCE: harder, valuable screens; WHEN TO PATENT: NOVEL METHOD/LIBRARY/ANALYSIS WITH MEASURED PERFORMANCE: file once a method shows measured results (screen sensitivity/specificity (hit recovery) + library quality (on/off-target) + readout dimensionality (single-cell) + in vivo capability + reproducibility + target-discovery validation) vs. standard-pooled-KO baselines — measured screen power, readout richness, and target-discovery validation are the critical CRISPR-screening IP metrics; KEY FTO CHECKLIST: Broad/UC foundational CRISPR-Cas9 (LICENSE required — famous dispute); Broad/GPP pooled screening + Brunello/GeCKO library + Doench design rules; CRISPRi dCas9-repressor knockdown; CRISPRa dCas9-activator; pooled lentiviral sgRNA screen/enrichment-dropout; Perturb-seq/CROP-seq single-cell (10x FTO); in vivo/FACS/reporter complex readout; base/prime-editing variant-effect/saturation screen; MAGeCK/hit-calling analysis; DepMap dependency/synthetic-lethality/target discovery; published/shared library nuance; platform vs target-discovery model.